A. Burgin

发表

Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.

D. Cacchiarelli, T. Mikkelsen, G. Getz, 2016, Cell reports.

Structural Impact of the Leukemia Drug 1-β-d-Arabinofuranosylcytosine (Ara-C) on the Covalent Human Topoisomerase I-DNA Complex*

Y. Pommier, A. Burgin, L. Stewart, 2003, The Journal of Biological Chemistry.

Structures of three classes of anticancer agents bound to the human topoisomerase I-DNA covalent complex.

Y. Pommier, A. Burgin, L. Stewart, 2005, Journal of medicinal chemistry.

Corrections to Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography

M. Gurney, O. Magnusson, A. Burgin, 2010, Journal of Medicinal Chemistry.

Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography†

Brian Pease, Lance J. Stewart, Alex B. Burgin, 2009, Journal of medicinal chemistry.

Mechanisms of camptothecin resistance by human topoisomerase I mutations.

Yves Pommier, Lance Stewart, Y. Pommier, 2004, Journal of molecular biology.

Small molecule allosteric modulators of phosphodiesterase 4.

M. Gurney, O. Magnusson, A. Burgin, 2011, Handbook of experimental pharmacology.

Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases

H. Ke, R. Taussig, A. Burgin, 2012, Cell.

Structural model of the dimeric Parkinson’s protein LRRK2 reveals a compact architecture involving distant interdomain contacts

M. Ueffing, N. Janjić, A. Burgin, 2016, Proceedings of the National Academy of Sciences.

HIGHLY EFFICIENT SYNTHESIS OF 2'-O-AMINO NUCLEOSIDES AND THEIR INCORPORATION IN HAMMERHEAD RIBOZYMES

A. Karpeisky, L. Beigelman, A. Burgin, 1998 .

2′-O-Methyl Thiomethyl Modifications in Hammerhead Ribozymes

A. Karpeisky, N. Usman, L. Beigelman, 1997 .

Quinolone action against human topoisomerase IIalpha: stimulation of enzyme-mediated double-stranded DNA cleavage.

N. Osheroff, K. Bromberg, A. Burgin, 2003, Biochemistry.

Structure–function analysis of the SHOC2–MRAS–PP1C holophosphatase complex

D. Root, A. Stamford, F. McCormick, 2022, Nature.

Regulation of site-speciﬁc recombination by the C-terminus of l integrase

A. Burgin, R. Gumport, R. Kazmierczak, 2022 .

Influence of Metal Ions on the Ribonuclease P Reaction

N. Pace, Elizabeth S. Haas, A. Burgin, 1992 .

The scale of demographic heterogeneity in a population of Peromyscus leucopus

A. Burgin, D. Krohne, 2004, Oecologia.

A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex

K. Kohn, Y. Pommier, A. Burgin, 2006, Molecular Cancer Therapeutics.

Identification of cancer cytotoxic modulators of PDE3A by predictive chemogenomics

Benito Munoz, Paul A Clemons, Aviad Tsherniak, 2015, Nature chemical biology.

The mechanism of topoisomerase I poisoning by a camptothecin analog

Lance Stewart, Michael D Feese, A. Burgin, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Mapping the active site of ribonuclease P RNA using a substrate containing a photoaffinity agent.

N. Pace, A. Burgin, A. Burgin, 1990, The EMBO journal.

Chemically modified hammerhead ribozymes with improved catalytic rates.

A. Karpeisky, N. Usman, L. Beigelman, 1996, Biochemistry.

Synthesis and use of DNA containing a 5'-bridging phosphorothioate as a suicide substrate for type I DNA topoisomerases.

A. Burgin, A B Burgin, 2001, Methods in molecular biology.

Selection, design, and characterization of a new potentially therapeutic ribozyme.

A. Beaudry, L. Beigelman, A. Burgin, 2002, RNA.

Uncoupling the Chemical Steps of Telomere Resolution by ResT*

A. Burgin, G. Chaconas, K. Kobryn, 2005, Journal of Biological Chemistry.

Unique motifs and hydrophobic interactions shape the binding of modified DNA ligands to protein targets

Daniel O'Connell, Larry Gold, Nebojsa Janjic, 2012, Proceedings of the National Academy of Sciences.

Modified nucleosides for ribozyme structure–activity studies

A. Karpeisky, N. Usman, L. Beigelman, 1996 .

The excision of intervening sequences from salmonella 23S ribosomal RNA

N. Pace, D. Lane, A. Burgin, 1990, Cell.

Plasmid RK2 ParB Protein: Purification and Nuclease Properties

A. Burgin, D. Helinski, H. Schwab, 1999, Journal of bacteriology.

Use of divalent metal ions in the dna cleavage reaction of human type II topoisomerases.

N. Osheroff, A. Burgin, J. Deweese, 2009, Biochemistry.

A Two-drug Model for Etoposide Action against Human Topoisomerase IIα*

N. Osheroff, K. Bromberg, A. Burgin, 2003, The Journal of Biological Chemistry.

Melanoplus sanguinipes entomopoxvirus DNA topoisomerase: site-specific DNA transesterification and effects of 5'-bridging phosphorothiolates.

A. Burgin, S. Shuman, B. O. Krogh, 1999, Virology.

DNA Contacts Stimulate Catalysis by a Poxvirus Topoisomerase*

F. Bushman, A. Burgin, Y. Hwang, 1999, The Journal of Biological Chemistry.

Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease

M. Gurney, A. Burgin, Emily C. D’Amato, 2014, Neurotherapeutics.

Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety

Timothy Hagen, Jasbir Singh, M. Gurney, 2010, Nature Biotechnology.

Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues.

A. Burgin, B. Staker, A. Raymond, 2004, Journal of molecular biology.

Structure and function of a cyanophage-encoded peptide deformylase

Robert A Edwards, Anca M Segall, Forest Rohwer, 2013, The ISME Journal.

Genomic deletions and rearrangements in monkeypox virus from the 2022 outbreak, USA

H Zhao, A. Burgin, Dakota T. Howard, 2022, bioRxiv.

Substrate Specificity of Tyrosyl-DNA Phosphodiesterase I (Tdp1)*

A. Burgin, B. Staker, A. Raymond, 2005, Journal of Biological Chemistry.

Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I.

A. Burgin, A. Raymond, M. Rideout, 2004, Nucleic acids research.

Human topoisomerase IIalpha possesses an intrinsic nucleic acid specificity for DNA ligation. Use of 5' covalently activated oligonucleotide substrates to study enzyme mechanism.

N. Osheroff, K. Bromberg, A. Burgin, 2002, The Journal of biological chemistry.

Human Topoisomerase IIα Possesses an Intrinsic Nucleic Acid Specificity for DNA Ligation

N. Osheroff, K. Bromberg, A. Burgin, 2002, The Journal of Biological Chemistry.

Human topoisomerase IIα uses a two-metal-ion mechanism for DNA cleavage

N. Osheroff, A. Burgin, J. Deweese, 2008, Nucleic acids research.

Using 3'-bridging phosphorothiolates to isolate the forward DNA cleavage reaction of human topoisomerase IIalpha.

N. Osheroff, A. Burgin, J. Deweese, 2008, Biochemistry.

Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage

A. Burgin, L. Stewart, B. Staker, 2005 .

Gene Composer: database software for protein construct design, codon engineering, and gene synthesis

John Walchli, Lance Stewart, Alex Burgin, 2009, BMC biotechnology.

Discovery of triazines as selective PDE4B versus PDE4D inhibitors.

M. Gurney, A. Burgin, T. Hagen, 2014, Bioorganic & medicinal chemistry letters.

Substitution of Conserved Residues within the Active Site Alters the Cleavage Religation Equilibrium of DNA Topoisomerase I*

M. Bjornsti, A. Burgin, M. van der Merwe, 2004, Journal of Biological Chemistry.

Catalytic Residues of the Telomere Resolvase ResT

A. Burgin, G. Chaconas, Sandra L. Wilson, 2004, Journal of Biological Chemistry.

Small molecules that inhibit TNF signalling by stabilising an asymmetric form of the trimer

Benjamin P. Cossins, T. Ceska, A. Lawson, 2019, Nature Communications.

Functional analysis of the C-terminal domains of the site-specific recombinases XerC and XerD.

D. Sherratt, A. Burgin, H. Ferreira, 2003, Journal of molecular biology.

Regulation of site-specific recombination by the C-terminus of λ integrase

A. Burgin, R. Gumport, R. Kazmierczak, 2002 .

Non-helical DNA Triplex Forms a Unique Aptamer Scaffold for High Affinity Recognition of Nerve Growth Factor.

H. Hishigaki, D. Schneider, Shashi Gupta, 2015, Structure.

A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases

B. Schmidt, N. Osheroff, J. Berger, 2010, Nature.

Challenging the state of the art in protein structure prediction: Highlights of experimental target structures for the 10th Critical Assessment of Techniques for Protein Structure Prediction Experiment CASP10

Marco Biasini, Victor Seguritan, Forest Rohwer, 2014, Proteins.

Phage Phenomics: Physiological Approaches to Characterize Novel Viral Proteins

Peter Salamon, Forest Rohwer, Robert A. Edwards, 2015, Journal of visualized experiments : JoVE.

Metal ion interactions in the DNA cleavage/ligation active site of human topoisomerase IIalpha.

N. Osheroff, A. Burgin, F. Guengerich, 2009, Biochemistry.

Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV

N. Osheroff, K. Neuman, A. Burgin, 2011, Nucleic acids research.

Regulation of site-specific recombination by the C-terminus of lambda integrase.

A. Burgin, R. Gumport, R. Kazmierczak, 2002, Nucleic acids research.

Relative success of residents and immigrants in Peromyscus leucopus

A. Burgin, D. Krohne, 1987 .

Structural basis for the design of selective phosphodiesterase 4B inhibitors.

David Fox, M. Gurney, A. Burgin, 2014, Cellular signalling.

Phenotypic Characterizati on of a Comprehensive Set of MAPK 1 / ERK 2 Missense Mutants Graphical

D. Cacchiarelli, T. Mikkelsen, G. Getz, 2016 .

Some of the most interesting CASP11 targets through the eyes of their authors

Victor Seguritan, Thomas S. Peat, Forest Rohwer, 2015, Proteins.

Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3'-para-nitrophenyl phosphate ester.

A. Burgin, S. Shuman, C. Cheng, 2000, Nucleic Acids Research.

Tyrosyl-DNA phosphodiesterase (Tdp1) (3'-phosphotyrosyl DNA phosphodiesterase).

A. Burgin, A. Raymond, 2006, Methods in enzymology.

DNA ligation catalyzed by human topoisomerase II alpha.

N. Osheroff, K. Bromberg, A. Burgin, 2004, Biochemistry.

A Maltose-Binding Protein Fusion Construct Yields a Robust Crystallography Platform for MCL1

T. Golub, G. Wei, Z. Ni, 2015, PloS one.

Genomic Surveillance for SARS-CoV-2 Variants: Predominance of the Delta (B.1.617.2) and Omicron (B.1.1.529) Variants — United States, June 2021–January 2022

Samuel S. Shepard, Richard A. Stanton, A. MacNeil, 2022, MMWR. Morbidity and mortality weekly report.

A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases.

A. Burgin, H. Nash, Shu-wei Yang, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Combined protein construct and synthetic gene engineering for heterologous protein expression and crystallization using Gene Composer

John Walchli, Lance Stewart, Alex Burgin, 2009, BMC biotechnology.

Phosphodiesterase-4 (PDE4) Molecular Pharmacology and Alzheimer’s Disease

M. Gurney, A. Burgin, Emily C. D’Amato, 2014, Neurotherapeutics.

Artificial Neural Networks Trained to Detect Viral and Phage Structural Proteins

Victor Seguritan, Peter Salamon, Alex B. Burgin, 2012, PLoS Comput. Biol..

In vitro selection of a novel nuclease-resistant RNA phosphodiesterase.

A. Beaudry, L. Beigelman, A. Burgin, 2000, Chemistry & biology.